BACKGROUND & AIMS There is a possible significant difficulty in differentiating between non-specific colitis (NSC) and early IBD patients with no cardinal endoscopic features. This clarifies the need to find markers with high sensitivity and specificity for distinguishing between both and other forms of specific colitis. The aim of this study to investigate the ability to use a chemokine panel (CCR9, CD146 and Foxp3) among patients with lower gastrointestinal symptoms found to have NSC (but do not have current IBD) to predict which patients progress to/develop future IBD or other diagnoses of specific colitis. METHODS Colonoscopy was done for 182 patients complaining of chronic diarrhea and or constipation, abdominal distention and pain with negative history for IBD, after Histopathological evaluation; 138 cases showing non-specific inflammation submitted for further immunohistochemical CCR9, CD146 and Foxp3 staining. On follow up patients with persistent symptoms or worsen symptoms recolonoscopy was done followed by Histopathological examination of samples and compared by the earlier results. RESULTS The studied markers expressed significantly in IBD patients differentiating them from NSC patients (p < 0.001) except for CCR9 expression was statistically insignificant in CD patients (p = 0.528). According to the ROC curves in prediction of progression using studied panel, the use of studied markers in combination was more statistically significant in comparison to each marker alone. Median follow up for studied patients was 12 months. CONCLUSIONS This panel of markers holds a promising hope for early IBD as predictive markers, discriminating IBD from NSC and as potential therapeutic targets.

中文翻译：

---

非特异性结肠炎趋化因子组的免疫组织化学染色可预测未来的 IBD 诊断

背景和目的 区分非特异性结肠炎 (NSC) 和没有主要内窥镜特征的早期 IBD 患者可能存在重大困难。这阐明了需要找到具有高灵敏度和特异性的标记以区分这两种形式的特定结肠炎和其他形式的特定结肠炎。本研究的目的是调查在发现患有 NSC（但目前没有 IBD）的下消化道症状患者中使用趋化因子面板（CCR9、CD146 和 Foxp3）来预测哪些患者进展为/发展为未来 IBD 或特定结肠炎的其他诊断。方法对182例主诉慢性腹泻和/或便秘、腹胀和疼痛且IBD阴性病史的患者进行结肠镜检查，经组织病理学评估；138 例表现出非特异性炎症的病例提交进一步免疫组织化学 CCR9、CD146 和 Foxp3 染色。对有持续症状或症状恶化的患者进行再结肠镜检查，随后对样本进行组织病理学检查，并与早期结果进行比较。结果 研究的标志物在 IBD 患者中显着表达，将它们与 NSC 患者区分开来（p < 0.001），除了 CCR9 表达在 CD 患者中无统计学意义（p = 0.528）。根据使用研究组预测进展的 ROC 曲线，与单独使用每个标记相比，组合使用研究标记在统计上更显着。研究患者的中位随访时间为 12 个月。结论 这组标志物为早期 IBD 作为预测标志物带来了希望，